Fog City Capital

Ad-Lib.io is a digital creative technology and service business based in the UK, specializing in the automation and management of creative assets for digital advertising. The company partners with platforms like Facebook and DoubleClick to enhance the efficiency of digital creative deployment. Ad-Lib.io does not engage in media buying; instead, it focuses on delivering optimized creative solutions. Its offerings include dynamic video capabilities, A/B testing, and an optimization algorithm, all designed to streamline workflows and improve campaign performance. The platform is engineered to save clients significant time—up to 46%—and enhance performance by as much as 80%, providing a comprehensive service that supports global brands in their digital advertising efforts.

Ad-Lib.io is a digital creative technology and service business based in the UK, specializing in the automation and management of creative assets for digital advertising. The company partners with platforms like Facebook and DoubleClick to enhance the efficiency of digital creative deployment. Ad-Lib.io does not engage in media buying; instead, it focuses on delivering optimized creative solutions. Its offerings include dynamic video capabilities, A/B testing, and an optimization algorithm, all designed to streamline workflows and improve campaign performance. The platform is engineered to save clients significant time—up to 46%—and enhance performance by as much as 80%, providing a comprehensive service that supports global brands in their digital advertising efforts.

Visual IQ produces the world’s most powerful cross channel marketing attribution software products. As a pioneer in the space, the company has been offering products since 2006. Its SaaS-based IQ Intelligence Suite reveals cross channel performance insights hidden deep within companies’ marketing data, providing actionable recommendations and optimized media plans to improve marketing effectiveness. These recommendations enable marketers and agencies to adjust their advertising strategies and tactics to significantly increase marketing ROI across their entire marketing mix – both online and offline. The functionality behind these products combines a powerful, user-friendly interface with multi-dimensional fractional attribution science and predictive analytics that clearly and accurately show marketers where opportunities exist for improvement. Visual IQ was named a leader in cross channel attribution in 2014 by a leading market research firm, won The Drum's 2015 Digital Trading Award for Best Attribution Solution, won the 2014 ASPY Award for Best Data or Analytics Solution, and was a finalist in the Digital Analytics Association Excellence Awards in 2013, 2014 and 2015. The company is a member of the Advertising Technology, Data, Public Policy and CFO Councils of the IAB, as well as on the Standards Committee of the Digital Analytics Association.

Cianna Medical, Inc., a women’s health company, develops medical technologies for treating breast cancer. The company offers SAVI SCOUT, a wire-free radar localization solution for breast tumor localization; and SAVI Brachy, a solution to deliver a highly-precise dose of radiation only to the tissue where the cancer is likely to reoccur. It also offers BrachyBytes, an e-newsletter that features interviews with experts in breast brachytherapy. The company was incorporated in 2007 and is based in Aliso Viejo, California. As of November 13, 2018, Cianna Medical, Inc. operates as a subsidiary of Merit Medical Systems, Inc.

Visual IQ produces the world’s most powerful cross channel marketing attribution software products. As a pioneer in the space, the company has been offering products since 2006. Its SaaS-based IQ Intelligence Suite reveals cross channel performance insights hidden deep within companies’ marketing data, providing actionable recommendations and optimized media plans to improve marketing effectiveness. These recommendations enable marketers and agencies to adjust their advertising strategies and tactics to significantly increase marketing ROI across their entire marketing mix – both online and offline. The functionality behind these products combines a powerful, user-friendly interface with multi-dimensional fractional attribution science and predictive analytics that clearly and accurately show marketers where opportunities exist for improvement. Visual IQ was named a leader in cross channel attribution in 2014 by a leading market research firm, won The Drum's 2015 Digital Trading Award for Best Attribution Solution, won the 2014 ASPY Award for Best Data or Analytics Solution, and was a finalist in the Digital Analytics Association Excellence Awards in 2013, 2014 and 2015. The company is a member of the Advertising Technology, Data, Public Policy and CFO Councils of the IAB, as well as on the Standards Committee of the Digital Analytics Association.

Cianna Medical, Inc., a women’s health company, develops medical technologies for treating breast cancer. The company offers SAVI SCOUT, a wire-free radar localization solution for breast tumor localization; and SAVI Brachy, a solution to deliver a highly-precise dose of radiation only to the tissue where the cancer is likely to reoccur. It also offers BrachyBytes, an e-newsletter that features interviews with experts in breast brachytherapy. The company was incorporated in 2007 and is based in Aliso Viejo, California. As of November 13, 2018, Cianna Medical, Inc. operates as a subsidiary of Merit Medical Systems, Inc.

Proprius Pharmaceuticals is a San Diego-based drug developer focused on rheumatology and autoimmune diseases. The company offers two early clinical-stage therapeutic candidates comprising a product to treat pain and a product to treat rheumatoid arthritis. Proprius Pharmaceuticals was founded in 2005.

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing proprietary branded prescription therapeutics to address significant medical needs and patient dissatisfaction. The company is actively involved in in-licensing, developing, and marketing products, particularly in the central nervous system therapeutic area. Somaxon is currently promoting Silenor®, the first and only nonscheduled prescription medication approved in the United States for the treatment of sleep maintenance insomnia. In addition to its focus on insomnia, the company has experience in developing products for other medical conditions, including middle ear infections, head lice, and cough and cold.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.

Guava Technologies, Inc. is a biotechnology and medical device company specializing in the development and manufacturing of flow cytometry systems. Founded in 1998 and headquartered in Hayward, California, the company provides a range of products designed for applications in cell biology research, drug discovery, and clinical diagnostics, with a specific focus on HIV/AIDS monitoring. Its offerings include assays for cell counting and viability, antibody quantification, apoptosis, cell cycle, cytotoxicity, and cell proliferation. Guava Technologies serves various markets, including life science research and core flow cytometry, contributing to advancements in cellular analysis. The company operates as a subsidiary of Millipore Corp.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.